阿帕他胺治疗转移性去势敏感性前列腺癌:TITAN研究最终生存分析
PURPOSE: The first interim analysis of the phase III, randomized, placebo-controlled TITAN study showed that apalutamide significantly improved overall survival (OS) and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC…
要点
- 阿帕他胺联合ADT降低死亡风险35%,校正交叉后降低48%。
- 两组健康相关生活质量维持,安全性与此前报告一致。
核心结论
- TITAN最终分析证实,尽管存在交叉,阿帕他胺联合ADT仍改善mCSPC患者总生存,延迟去势抵抗,维持生活质量,安全性一致。
研究设计与样本
- III期随机双盲安慰剂对照TITAN研究,纳入1052例mCSPC患者,1:1随机接受阿帕他胺240mg每日一次或安慰剂联合持续ADT。
- 2019年1月揭盲后允许安慰剂组患者交叉接受阿帕他胺,最终分析无正式统计重测和多重性校正。
主要发现
- 中位随访44.0个月,发生405例OS事件,208例(39.5%)安慰剂组患者交叉至阿帕他胺。
- 阿帕他胺组中位治疗 duration 39.3个月,安慰剂组20.2个月,交叉组15.4个月。
临床怎么用
- 对于mCSPC患者,阿帕他胺联合ADT可作为改善生存、延迟去势抵抗的治疗选择。
局限性
- 最终分析无正式统计重测和多重性校正。
- 安慰剂组交叉可能影响OS的正式统计推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The first interim analysis of the phase III, randomized, placebo-controlled TITAN study showed that apalutamide significantly improved overall survival (OS) and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving ongoing androgen deprivation therapy (ADT). Herein, we report final efficacy and safety results after unblinding and placebo-to-apalutamide crossover. METHODS: Patients with mCSPC (N = 1,052) were randomly assigned 1:1 to receive apalutamide (240 mg QD) or placebo plus ADT. After unblinding in January 2019, placebo-treated patients were allowed to receive apalutamide. Efficacy end points were updated using the Kaplan-Meier method and Cox proportional-hazards model without formal statistical retesting and adjustment for multiplicity. Change from baseline in Functional Assessment of Cancer Therapy-Prostate total score was assessed. RESULTS: With a median follow-up of 44.0 months, 405 OS events had occurred and 208 placebo-treated patients (39.5%) had crossed over to apalutamide. The median treatment duration was 39.3 (apalutamide), 20.2 (placebo), and 15.4 months (crossover). Compared with placebo, apalutamide plus ADT significantly reduced the risk of death by 35% (median OS not reached v 52.2 months; hazard ratio, 0.65; 95% CI, 0.53 to 0.79; P < .0001) and by 48% after adjustment for crossover (hazard ratio, 0.52; 95% CI, 0.42 to 0.64; P < .0001). Apalutamide plus ADT delayed second progression-free survival and castration resistance (P < .0001 for both). Health-related quality of life, per total Functional Assessment of Cancer Therapy-Prostate, in both groups was maintained through the study. Safety was consistent with previous reports. CONCLUSION: The final analysis of TITAN confirmed that, despite crossover, apalutamide plus ADT improved OS, delayed castration resistance, maintained health-related quality of life, and had a consistent safety profile in a broad population of patients with mCSPC.
引用
- Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol. 2021. PMID: 33914595. doi:10.1200/JCO.20.03488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。